Current [tmco]
Phase [tmco]
Ii [aapp]
Proprotein Convertase [aapp, enzy]
Subtilisin [aapp, enzy]
kexin [aapp, enzy]
Inhibitor [qlco]
Therapies [topp]
Dyslipidaemia [dsyn]
Introduction [hlca]
reduction [npop]
Plasma [bdsu]
Low density lipoprotein [aapp, bacs, lipd]
Cholesterol [bacs, strd]
Concentration [menp]
Statins [orch, phsu]
CARDIOVASCULAR [bdsy]
Outcome [ftcn]
lack [qlco]
Efficacy [qlco]
Intolerance [orgf]
Statins [orch, phsu]
Patients [podg]
Alternative [cnce]
Treatments [topp]
Currently [tmco]
Available [ftcn]
Non [ftcn]
Statin [orch, phsu]
Alternative [cnce]
Bile Acid Sequestrants [phsu]
cholesterol inhibitor [phsu]
Absorption [npop]
ezetimibe [orch, phsu]
Niacin preparation [orch, phsu, vita]
Based [ftcn]
Fibrates [orch, phsu]
limitations [ftcn]
New Agents [clas]
Cholesterol, LDL [bacs, strd]
reduction [npop]
Cholesterol ester transfer protein [aapp, bacs]
inhibitors [chvf]
Microsomal Triglyceride Transfer Protein Inhibitor [phsu]
lomitapide [orch, phsu]
Apolipoprotein B [aapp, bacs]
antisense oligonucleotide [bacs, irda, nnon]
mipomersen [nnon, phsu]
Several [qnco]
molecules [sbst]
arrested [dsyn]
Interfere [qlco]
Proprotein Convertase [aapp, enzy]
Subtilisin [aapp, enzy]
kexin [aapp, enzy]
Covered [ftcn]
Various [irda]
Proprotein Convertase [aapp, enzy]
Subtilisin [aapp, enzy]
kexin [aapp, enzy]
inhibitors [chvf]
human data [inpr, resa]
Available [ftcn]
Monoclonal Antibodies [aapp, imft]
Proprotein Convertase [aapp, enzy]
Subtilisin [aapp, enzy]
kexin [aapp, enzy]
Two [qnco]
Advanced [qlco]
Phase [tmco]
Ii [aapp]
Study [mnob]
Agent [chvf]
Combination [qlco]
Statins [orch, phsu]
Show [inpr]
reductions [npop]
Cholesterol, LDL [bacs, strd]
Acceptable [qlco]
Safety [hcpp]
TOLERABILITY [resa]
Expert Opinion [cnce]
Biochemical [ftcn]
Efficacy [qlco]
Clinical [qlco]
Efficacy [qlco]
reflected [menp]
reduction [npop]
CARDIOVASCULAR [bdsy]
End Point [qlco]
To [qlco]
Show [inpr]
Two [qnco]
Leading [tmco]
Monoclonal Antibodies [aapp, imft]
Issue [fndg]
Evaluated [ftcn]
Agent [chvf]
Long-term [tmco]
development [phsf]
Rare [tmco]
adverse effects [ftcn]
Potential [qlco]
Attenuation [acty]
Efficacy [qlco]
